CNCR
Closed
Loncar Cancer Immunotherapy Etf
9.02
0.00 (0.00%)
Last Update: 03 Jun 2025 16:30:00
Yesterday: 9.02
Day's Range: 9.02 - 9.02
Send
sign up or login to leave a comment!
When Written:
11.95
The Loncar Cancer Immunotherapy ETF (ticker symbol: CNCR) is an exchange-traded fund that invests in companies involved in cancer immunotherapy research and development. The fund was created by Brad Loncar, a biotech investor and founder of Loncar Investments LLC.
The CNCR ETF tracks the Loncar Cancer Immunotherapy Index, which includes companies that are developing cancer treatments that harness the immune system to fight cancer. These companies include large pharmaceutical companies such as Merck and Bristol-Myers Squibb, as well as smaller biotech companies that are focused on cancer immunotherapy.
The CNCR ETF was launched in October 2015 and has since gained popularity among investors who are interested in the growing field of cancer immunotherapy. The fund has an expense ratio of 0.79% and has over $750 million in assets under management as of June 2021.
Investing in the CNCR ETF provides investors with exposure to a diversified portfolio of companies that are at the forefront of cancer research and development. However, like all investments, there are risks involved, and investors should carefully consider their investment objectives, risk tolerance, and financial situation before investing in the CNCR ETF.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
The CNCR ETF tracks the Loncar Cancer Immunotherapy Index, which includes companies that are developing cancer treatments that harness the immune system to fight cancer. These companies include large pharmaceutical companies such as Merck and Bristol-Myers Squibb, as well as smaller biotech companies that are focused on cancer immunotherapy.
The CNCR ETF was launched in October 2015 and has since gained popularity among investors who are interested in the growing field of cancer immunotherapy. The fund has an expense ratio of 0.79% and has over $750 million in assets under management as of June 2021.
Investing in the CNCR ETF provides investors with exposure to a diversified portfolio of companies that are at the forefront of cancer research and development. However, like all investments, there are risks involved, and investors should carefully consider their investment objectives, risk tolerance, and financial situation before investing in the CNCR ETF.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!